Placenta, Fetal Liver, Sectional Ductus Venosus Volumes Examined by Three-dimensional Ultrasound in the Second Trimester
NCT06178250
3D SONOGRAPHY, DUCTUS VENOSUS VOLUME
Bursa, Turkey (Türkiye)
View Trial DetailsNCT Number: NCT07467148
The aim of this study is to evaluate the placental thickness-to-fetal weight ratio as a predictor of adverse pregnancy outcomes.
Trial opening soon.
Get Notified20 year–45 year
Female
Observational
The placenta is a vital organ that ensures normal fetal growth and development throughout pregnancy by mediating the exchange of oxygen, nutrients, waste products, and essential hormones between the mother and the fetus (1). Any structural or functional abnormality of the placenta can adversely affect fetal growth and pregnancy outcome, highlighting the importance of placental assessment in antenatal care (2).
Adverse pregnancy outcomes, including intrauterine growth restriction (IUGR), preterm birth, low birth weight, preeclampsia, fetal distress, and perinatal mortality, remain major contributors to maternal and neonatal morbidity and mortality worldwide. Early identification of high-risk pregnancies allows timely interventions, closer surveillance, and improved perinatal outcomes (3). However, advances in ultrasonography and antenatal care, reliable, non-invasive, and easily measurable predictors of adverse outcomes are still limited (4).
Ultrasonographic evaluation of placental morphology has emerged as a practical, non-invasive, and widely accessible method to assess placental health. Among the various parameters, placental thickness reflects placental growth, maturation, and potentially its functional capacity, correlating with gestational age and fetal weight in normal pregnancies. Abnormal placental thickness either decreased or increased has been associated with maternal and fetal pathological conditions (5).
A thin placenta is frequently linked to preeclampsia, IUGR, and chorioamnionitis, whereas a thick placenta defined as more than 3 cm before 20 weeks of gestation and greater than 5 cm at term is observed in Rh-negative pregnancies, gestational diabetes mellitus, and intrauterine infections, particularly primary maternal cytomegalovirus infection (6). Placentomegaly may also be associated with fetal anemia or hromosomal abnormalities such as triploidy, and may result from inflammation, edema, or compensatory hypertrophy secondary to placental insufficiency (7).
Maternal disorders often affect both the fetus and the placenta, making abnormal placental growth a potential marker for impaired fetal growth and adverse neonatal outcomes. Nevertheless, the predictive value of placental thickness alone remains uncertain (8).
Given its simplicity, reproducibility, and cost-effectiveness, ultrasonographic measurement of placental thickness and particularly the placental thickness-to-fetal weight ratio may provide a valuable tool for early detection of high-risk pregnancies. This could allow obstetricians to implement timely interventions, optimize delivery planning, and improve maternal and neonatal outcomes (9). Therefore, this study aims to evaluate the placental thickness-to-fetal weight ratio as a predictor of adverse pregnancy outcomes.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: From aug 2026 to aug 2029
Correlation of placental thickness-to-fetal weight ratio with individual adverse pregnancy outcomes
Contact information is provided by the study sponsor or research team.
Ahmed Mohamed Abbas, Professor
CONTACT
Radia Atef Elzokm, Resident doctor
CONTACT
Radia Atef Elzokm
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06178250
3D SONOGRAPHY, DUCTUS VENOSUS VOLUME
Bursa, Turkey (Türkiye)
View Trial Details